VanEck Associates’s Edwards Lifesciences EW Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $11.4M | Sell |
126,258
-13,722
| -10% | -$1.15M | 0.01% | 590 |
|
|
2026
Q1 | $11.2M | Sell |
139,980
-25,633
| -15% | -$2.11M | 0.01% | 566 |
|
|
2025
Q4 | $14.1M | Sell |
165,613
-20,251
| -11% | -$1.66M | 0.01% | 474 |
|
|
2025
Q3 | $14.5M | Sell |
185,864
-13,004
| -7% | -$1.02M | 0.01% | 434 |
|
|
2025
Q2 | $15.6M | Sell |
198,868
-31,401
| -14% | -$2.34M | 0.02% | 376 |
|
|
2025
Q1 | $16.7M | Buy |
230,269
+59,167
| +35% | +$4.23M | 0.02% | 351 |
|
|
2024
Q4 | $12.7M | Buy |
171,102
+44,338
| +35% | +$3.1M | 0.02% | 406 |
|
|
2024
Q3 | $8.95M | Buy |
126,764
+9,011
| +8% | +$655K | 0.01% | 479 |
|
|
2024
Q2 | $10.9M | Sell |
117,753
-24,329
| -17% | -$2.15M | 0.02% | 402 |
|
|
2024
Q1 | $13.6M | Sell |
142,082
-28,012
| -16% | -$2.35M | 0.02% | 337 |
|
|
2023
Q4 | $13M | Buy |
170,094
+24,605
| +17% | +$1.71M | 0.02% | 318 |
|
|
2023
Q3 | $10.1M | Buy |
145,489
+17,597
| +14% | +$1.41M | 0.02% | 343 |
|
|
2023
Q2 | $12.1M | Sell |
127,892
-7,933
| -6% | -$690K | 0.03% | 320 |
|
|
2023
Q1 | $11.2M | Buy |
135,825
+12,295
| +10% | +$966K | 0.03% | 328 |
|
|
2022
Q4 | $9.22M | Buy |
123,530
+6,676
| +6% | +$515K | 0.02% | 349 |
|
|
2022
Q3 | $9.66M | Buy |
116,854
+6,081
| +5% | +$585K | 0.03% | 318 |
|
|
2022
Q2 | $10.5M | Sell |
110,773
-2,079
| -2% | -$215K | 0.03% | 320 |
|
|
2022
Q1 | $13.3M | Buy |
112,852
+17,512
| +18% | +$1.96M | 0.03% | 313 |
|
|
2021
Q4 | $12.4M | Buy |
95,340
+16,084
| +20% | +$1.88M | 0.03% | 335 |
|
|
2021
Q3 | $8.97M | Buy |
79,256
+15,924
| +25% | +$1.82M | 0.02% | 358 |
|
|
2021
Q2 | $6.56M | Buy |
63,332
+306
| +0.5% | +$28.8K | 0.02% | 409 |
|
|
2021
Q1 | $5.27M | Buy |
63,026
+6,847
| +12% | +$579K | 0.01% | 429 |
|
|
2020
Q4 | $5.13M | Buy |
56,179
+8,250
| +17% | +$684K | 0.01% | 375 |
|
|
2020
Q3 | $3.83M | Buy |
47,929
+5,742
| +14% | +$448K | 0.01% | 374 |
|
|
2020
Q2 | $2.92M | Buy |
42,187
+7,444
| +21% | +$529K | 0.01% | 425 |
|
|
2020
Q1 | $2.18M | Buy |
34,743
+3,420
| +11% | +$247K | 0.01% | 436 |
|
|
2019
Q4 | $2.44M | Buy |
31,323
+28,248
| +919% | +$2.21M | 0.01% | 485 |
|
|
2019
Q3 | $225K | Buy |
3,075
+489
| +19% | +$34.4K | ﹤0.01% | 724 |
|
|
2019
Q2 | $159K | Buy |
+2,586
| New | +$156K | ﹤0.01% | 724 |
|
|
2017
Q2 | – | Sell |
-9,759
| Closed | -$306K | – | 777 |
|
|
2017
Q1 | $306K | Buy |
9,759
+708
| +8% | +$22.2K | ﹤0.01% | 643 |
|
|
2016
Q4 | $283K | Buy |
9,051
+897
| +11% | +$29.1K | ﹤0.01% | 639 |
|
|
2016
Q3 | $328K | Buy |
8,154
+2,115
| +35% | +$79.7K | ﹤0.01% | 616 |
|
|
2016
Q2 | $201K | Buy |
6,039
+1,434
| +31% | +$49.1K | ﹤0.01% | 626 |
|
|
2016
Q1 | $135K | Buy |
4,605
+765
| +20% | +$21.1K | ﹤0.01% | 643 |
|
|
2015
Q4 | $101K | Buy |
3,840
+1,152
| +43% | +$29.9K | ﹤0.01% | 619 |
|
|
2015
Q3 | $64K | Buy |
2,688
+396
| +17% | +$9.56K | ﹤0.01% | 663 |
|
|
2015
Q2 | $54K | Buy |
2,292
+462
| +25% | +$10.4K | ﹤0.01% | 690 |
|
|
2015
Q1 | $43K | Buy |
1,830
+876
| +92% | +$19.7K | ﹤0.01% | 700 |
|
|
2014
Q4 | $20K | Buy |
+954
| New | +$19.2K | ﹤0.01% | 720 |
|
Other funds holding EW
VanEck Associates's EW Position: Q2 2026 in Review
VanEck Associates reduced its Edwards Lifesciences (EW) stake by 9.8% in Q2 2026, selling an estimated $1.15M and leaving 126,258 shares worth $11.4M. The position accounts for 0.01% of the portfolio, ranked #590.
VanEck Associates first reported a position in EW in Q4 2014 and has held it in 39 quarters since. The position peaked at $16.7M in Q1 2025. 1,325 funds tracked by Wall St. Rank hold EW as of Q2 2026.
- VanEck Associates held 126,258 shares of Edwards Lifesciences worth $11.4M as of Q2 2026.
- VanEck Associates sold 13,722 Edwards Lifesciences shares in Q2 2026, an estimated $1.15M.
- Edwards Lifesciences made up 0.01% of VanEck Associates's portfolio in Q2 2026, its #590 holding.
- VanEck Associates first reported a position in Edwards Lifesciences in Q4 2014 and has held it in 39 quarters since.
- VanEck Associates's Edwards Lifesciences position peaked at $16.7M in Q1 2025.
- 1,325 funds tracked by Wall St. Rank held Edwards Lifesciences as of Q2 2026.
Based on VanEck Associates's 13F filing for Q2 2026, filed 14 Aug 2026.